January 16, 2021

The Niche

Trusted stem cell blog & resources

IPSC clinical study

2 min read

Ring the bell for a stem cell milestone. There’s been a whole lot of commotion about the NEJM article yesterday documenting the experiences of three women with macular degeneration who were blinded by non-FDA approved stem cell eye injections of fat stem cells at a business in Florida, but in the same issue of the journal there also was some encouraging stem cell news that came in the form of essentially a mirror image of the bad news paper. We can call it the “stem cell …Read More

1 min read

Nominations are open starting today for the Stem Cell Person of the Year Award for 2016. Please email me your nominations: knoepflerATucdavisDOTedu. This is a unique award as it is given to an individual who has taken risks to help others within the stem cell field and they based their actions on outside-the-box thinking. Another unusual aspect is that anyone is eligible for the prize whether you are a scientist, physician, patient, writer, student, etc. There are also no geographic restrictions. The winner receives …Read More

1 min read

Some good news today as the pioneering induced pluripotent stem (IPS) cell trial led by Dr. Masayo Takahashi will resume. This clinical study with a focus on macular degeneration has been on hold for quite some time due to regulatory changes in Japan. There had also been concerns over mutations in the 2nd patient’s IPS cell product. As previous signs had indicated, the new clinical work will have an allogeneic focus, most likely drawing IPS cells from a bank. According to a Japan Times …Read More

3 min read

As many of you know, the pioneering, first of its kind IPS cell clinical study in Japan has been suspended as I first blogged about here.2020 Update: I believe a version of this study is ongoing. In the comments section of that blog post there has been a helpful overall discussion that has involved Dr. Masayo Takahashi, the leader of the IPS cell trial. It is great that Dr. Takahashi has been participating in this discussion and I commend her for that openness. This …Read More

9 min read

Masayo Takahashi (高橋 政代) on IPSC Trial for Macular Degeneration By Michael Cea Stem Cell Analyst & Advocate (editor’s note: piece was originally posted on Michael’s blog here; follow Michael on Twitter @msemporda) Having followed closely the developments in programs using pluripotent based therapeutics I was fortunate during ISSCR2015 to have the opportunity to sit down with Dr Masayo Takahashi to discuss her pioneering efforts to translate Shinya Yamanaka’s groundbreaking iPS technology for debilitating retinal conditions. As most everyone is aware, the first iteration of the …Read More

2 min read

The pioneering induced pluripotent stem cell (IPSC) clinical study in Japan led by top stem cell clinical researcher Dr. Masayo Takahashi has been stopped reports the WSJ in Japan. This development is confirmed by other sources and in a PDF report by RIKEN (in Japanese here). One patient was transplanted in September 2014 with their own IPSC-derived retinal pigment epithelial cells (using an innovative RPE sheet, see image) for treatment of macular degeneration. The study then moved on to a possible second patient, whose IPSC did …Read More

2 min read

Congratulations to Masayo Takahashi (高橋 政代), MD, PhD, the winner of the 2014 Stem Cell Person of the Year Award. Dr. Takahashi received this award including the $2,000 prize for her exceptional achievements in stem cell research in 2014. She was selected as the winner from a stellar group of top 12 finalists this year. Takahashi leads a team doing high-risk, high reward research that is conducting the first induced pluripotent stem cell (IPSC) clinical study in humans ever. I interviewed Takahashi at the beginning of this …Read More

5 min read

I invited Nobel Laureate Shinya Yamanaka to do an interview on the future of clinical translation of induced pluripotent stem cells (iPSC). He provides some intriguing new insights into the iPSC field and the broader stem cell arena. PK: The Takahashi Team’s active Clinical Study using iPSCs to make RPEs to treat Macular Degeneration has generated a great deal of excitement. Can you please share your perspectives on the importance of this work and the team involved?  SY: This is the first study to apply …Read More